Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review

2013 ◽  
Vol 30 (5) ◽  
pp. 512-524 ◽  
Author(s):  
M. J. Davies ◽  
J. J. Gagliardino ◽  
L. J. Gray ◽  
K. Khunti ◽  
V. Mohan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Real World ◽  
Factors Affecting

scholarly journals Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: do we need to treat it? A systematic review

Pancreatology ◽  
2018 ◽  
Vol 18 (5) ◽  
pp. 559-565 ◽  
Author(s):  
Gábor Zsóri ◽  
Dóra Illés ◽  
Viktória Terzin ◽  
Emese Ivány ◽  
László Czakó
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pancreatic Insufficiency ◽  
Exocrine Pancreatic Insufficiency

Early detection of cutaneous complications of insulin therapy in type 1 and type 2 diabetes mellitus

2021 ◽  
Author(s):  
Saurabh Arora ◽  
Neeraj Kumar Agrawal ◽  
Dhananjaya Melkunte Shanthaiah ◽  
Ashish Verma ◽  
Sanjay Singh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Early Detection ◽  
Insulin Therapy

scholarly journals Probiotics Contribute to Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Thanitsara Rittiphairoj ◽  
Krit Pongpirul ◽  
Kantima Janchot ◽  
Noel T Mueller ◽  
Tianjing Li
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
P Value ◽  
Short Term

ABSTRACT This systematic review aimed to evaluate the effectiveness and safety of probiotics for glycemic control in adults with impaired glucose control, including prediabetes and type 2 diabetes mellitus (T2DM). We searched PubMed, Embase, and Cochrane databases, and trial registries up to February 2019. We included randomized controlled trials (RCTs) of participants with prediabetes or T2DM. Eligible trials compared probiotics versus either placebo, no intervention, or comparison probiotics, or compared synbiotics versus prebiotics. Primary outcomes were mean change in fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) from baseline to short term (<12 wk) and long term (≥12 wk). We performed meta-analyses using the random-effects model. We included 28 RCTs (1947 participants). Overall, probiotics reduced FBG more than the placebo/no intervention group with a mean difference (MD) of –12.99 mg/dL (95% CI: –23.55, –2.42; P value: 0.016) over the short term; and –2.99 mg/dL (95% CI: –5.84, –0.13; P value: 0.040) over the long term. There was also some evidence for reduced HbA1c in the probiotics group at both short term (MD: –0.17; 95% CI: –0.37, 0.02; P value: 0.084) and long term (MD: –0.14; 95% CI: –0.34, 0.06; P value: 0.172), however, these did not reach statistical significance possibly because only a few trials reported HbA1c as an outcome. Subgroup analyses showed a greater reduction in HbA1c in participants not receiving insulin therapy than those receiving insulin therapy. Furthermore, the effect of probiotics on the reduction of FBG was more pronounced in participants with FBG >130 mg/dL and those not receiving insulin therapy than their counterparts. Probiotics were also effective in lowering serum cholesterol over the short and long term. In conclusion, we found that probiotics may have a glucose-lowering effect in T2DM participants. The effect appeared to be stronger in participants with poorly controlled diabetes and those not on insulin therapy. Systematic review registration: CRD42019121682.

scholarly journals Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus

JAMA ◽  
2003 ◽  
Vol 289 (17) ◽  
pp. 2254 ◽  
Author(s):  
Dawn E. DeWitt ◽  
Irl B. Hirsch
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy
Sign in / Sign up

Export Citation Format

Share Document